2nd Quarter - Report

AMERICAN ASSOCIATION FOR HOMECARE for AMERICAN ASSOCIATION FOR HOMECARE

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$170,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 16, 2018 $170,000 Replaced
2nd Quarter - Amendment Jul 20, 2018 $170,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues pertaining to durable medical equipment including: bidding, power wheelchairs, oxygen, diabetic supplies, negative pressure wound therapy, Medicare audits, sequestration; H.R. 750 - Ensuring Access to Quality Complex Rehabilitation Technology Act; H.R. 1361/S. 486/H.R. 3730 - To amend title XVIII of the Social Security Act to provide for the non-application of Medicare competitive acquisition rates to complex rehabilitative wheelchairs and accessories (Protecting Beneficiary Access to Complex Rehab Technology Act of 2017); Issues related to reimbursement cuts in noncompetitive bidding areas, all provisions; 21st Century Cures Act (H.R. 6/H.R. 34 in the 114th Congress), competitive bidding issues; Complex rehab technology accessories relating to competitive bidding; H.R. 2445 - the DMEPOS Access and Transparency Act of 2017 (DATA Act), all provisions; H.R. 4229 - Protecting HOME Access Act of 2017, all provisions; H.R. 2550 - Medicare Telehealth Parity Act of 2017, all provisions; H.R. 1625 - Consolidated Appropriations Act of 2018; issues pertaining to the Interim Final Rule (IFR) regarding non CB Area Relief for DME Items; Expanding and making permanent the Medicare power mobility device demonstration program; Audit and Appeal Fairness, Integrity, and Reforms in the Medicare Act, all provisions (S. 2368 in the 114th Congress); DME issues in the FY2019 President's Budget and ESRD/DEMPOS proposed rule.

LobbyistCovered position, as disclosed
KIM BRASON —
ASHLEY PLAUCHE —
THOMAS RYAN —
MINA UEHARA —
JAY WITTER —

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Government Accountability Office (GAO)

Bills named: S. 486 (115th), H.R. 6 (115th), H.R. 2550 (115th), H.R. 1625 (115th), H.R. 4229 (115th), S. 2368 (115th), H.R. 3730 (115th), H.R. 750 (115th), H.R. 2445 (115th), H.R. 34 (115th), H.R. 1361 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.